Corrigendum to: Tweak up-regulates endothelin-1 system in mouse and human endothelial cells (Cardiovascular Research (2017) 113:2 (207-221) DOI: 10.1093/cvr/cvw239);Tweak up-regulates endothelin-1 system in mouse and human endothelial cells

Cardiovascular Research

Volumn 113, Issue 2, 2017, Pages 207-221

  Martinez Miguel, Patricia ^a   Medrano Andres, Diana ^a   Griera Merino, Mercedes ^b   Ortiz, Alberto ^c   Rodriguez Puyol, Manuel ^b,d   Rodriguez Puyol, Diego ^a,d   Lopez Ongil, Susana ^a,d  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Instituto Reina Sofia de Investigacion Nefrol Ogica   (Spain)

Author keywords

Blood pressure; Endothelial cells; Endothelin converting enzyme 1; TWEAK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; ECE1 PROTEIN, HUMAN; ECE1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GEL MOBILITY SHIFT ASSAY; GENE DELETION; HUMAN; HUMAN CELL; HYPERTENSION; IN VIVO STUDY; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ASSAY; SINGLE DRUG DOSE; TRANSIENT TRANSFECTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR;

ANIMALS; BLOOD PRESSURE; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIN-CONVERTING ENZYMES; HUMANS; HYPERTENSION; IN VITRO TECHNIQUES; MALE; MICE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR NECROSIS FACTORS; UP-REGULATION;

EID: 85015164459     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx123     Document Type: Erratum

References (53)

1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia L, Browning JL TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-32410.
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7:411-425.
3. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999;274:33166-33176.
4. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837-846.
5. Bowerman M, Salsac C, Coque E, Eiselt E, Deschaumes RG, Brodovitch A, Burkly LC, Scamps D, Raoul C. TWEAK regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 2015;24:3440-3456
6. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEBJ 2007;21:1857-1869.
7. Cherry EM, Lee DW, JungJU, Sitcheran R. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-kB-inducing kinase (NIK) and noncanonical NF-kB signaling. Mol Cancer 2015;14:9.
8. Munoz-Garcia B, Martfn-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006;37:2044-2053.
9. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R, Burkly LC. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009;119:2058-2068.
10. Mustonen E, Ruskoaho H, Rysa J. Thrombospondin-4, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14: novel extracellular matrix modulating factors in cardiac remodelling. Ann Med 2012;44:793-804.
11. Novoyatleva T, Janssen W, Wietelmann A, Schermuly RT, Engel FB. TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy. Cytokine 2013;64:43-45.
12. Chen HN, Wang DJ, Ren MY, Wang QL, Sui SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of the rat cardiac fibroblasts via the NFkB pathway. Mol Biol Rep 2012;39:8231-8241.
13. Novoyatleva T, Schymura Y, Janssen W, Strobl F, Swiercz JM, Patra C, Posern G, Wietelmann A, Zheng TS, Schermuly RT, Engel FB. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol 2013;108:325.
14. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594-600.
15. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002;299:488-493.
16. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-8459.
17. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J. Blanco-Colio LM. Tumor necrosis factorlike weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009;29:2061-2068.
18. Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, Kockx MM, Daemen MJ, Heeneman S. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/-mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol 2009;29:2021-2027.
19. King VL Atherosclerosis: should we stop TWEAKing it? Arterioscler Thromb Vasc Biol 2009;29:1982-1983.
20. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial N-mono-methyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10:1025-1031.
21. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-2554.
22. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N EnglJ Med 1986;315:1046-1051.
23. Yanagisawa M, Kurihara S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
24. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-485.
25. Turner AJ, Tanzawa K Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX FASEBJ 1997;11:355-364.
26. Muller L, Barret A, Etienne E, Meidan R, Valdenaire O, Corvol P, Tougard C. Heterodimerization of endothelin-converting enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease. J Biol Chem 2003;278:545-555.
27. Ruschitzka F, Moehrlen U, Quaschning T, Lachat M, Noll G, Shaw S, Yang Z, Teupser D, Subkowski T, Turina MI, Luscher TF. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease. Circulation 2000;102:1086-1092.
28. Lopez-Ongil S, Saura M, Zaragoza C, Gonzalez-Santiago L, Rodriguez-Puyol M, Lowestein CJ, Rodriguez-Puyol D. Hydrogen peroxide regulation of bovine endothelin-converting enzyme-1. Free Radic Biol Med 2002;32:406-413.
29. Lopez-Ongil S, Senchak V, Saura M, Zaragoza C, Ames M, Ballermann B, Rodriguez-Puyol M, Rodriguez-Puyol D, Lowestein CJ. Superoxide regulation of endothelin-converting enzyme. J Biol Chem 2000;275:26423-26427.
30. Martinez-Miguel P, Raoch V, Zaragoza C, Valdivielso J.M, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. Endothelin converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins. J Lipid Res 2009;50:364-375.
31. Lopez-Ongil S, Diez-Marques ML, Griera M, Rodriguez-Puyol M, Rodriguez-Puyol D. Crosstalk between mesangial and endothelial cells: angiotensin II down-regulates endothelin-converting enzyme 1. Cell Physiol Biochem 2005;15:135-144.
32. Raoch V, Rodriguez-Pascual F, Lopez-Martinez V, Medrano-Andres D, Rodriguez-Puyol M, Lamas S, Rodriguez-Puyol D, Lopez-Ongil S. Nitric oxide decreases the expression of endothelin-converting enzyme-1 through mRNA destabilization. Arterioscler Thromb Vasc Biol 2011;31:2577-2585.
33. Martinez-Miguel P, Valdivielso JM, Medrano-Andres D, Roman-Garcia P, Cano-Penalver JL, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. The active form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells. Am J Physiol Endocrinol Metab 2014;307: E1085-E1096.
34. Martinez-Miguel P, Medrano-Andres D, Lopes-Martin V, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. Regulation of endothelin-converting (ECE-1) by the calcimimetic R-568. Pharmacol Res 2013;76:106-118.
35. Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. The peptide inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. BrJ Pharmacol 2007;152:313-322.
36. Uhlmann D, Witzigmann H, Senninger H, Hauss J, Spiegel HU. Protective role of an endothelin-converting enzyme inhibitor (FR901533) in hepatic ischemia/reperfusion injury. Microvasc Res 2001;62:43-54.
37. Berthiaume N, Yanagisawa M, Labonte J, D'Orleans-Juste P. Heterozygous knock-out of ETB receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 2000;36:1002-1007.
38. Ruiz-Torres MP, Griera M, Chamorro A, Diez-Marques ML, Rodriguez-Puyol D, Rodriguez-Puyol M. Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences. Cardiovasc Res 2009;82: 125-132.
39. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
40. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme-1 (ECE-1). J Biol Chem 1995;270: 29794-29798.
41. Han A, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
42. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH. A panel of biomarkers is associ-ated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014;66:130-139.
43. Ozyazgan S, Uzun H, Onal B, Tuzcu A, Ugurlu S, Andican G. Lectin-like oxidized LDL receptor-1 as a marker of endothelial dysfunction in Behcet's disease. Clin Exp Rheumatol 2013;31:71-76.
44. Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 2009;296:R1258-1267.
45. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complica-tions associated with endothelin-receptor blockade. Atherosclerosis 2002;160: 297-304.
46. Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Cytokine 2016;80:7-12.
47. Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol 2013;14:144.
48. Slomiany BL, Piotrowski J, Slomiany A. Up-regulation of endothelin-converting en-zyme-1 in gastric mucosal inflammatory responses to Helicobacter pylori lipopoly-saccharide. Biochem Biophys Res Commun 2000;267:801-805.
49. Filusch A, Zelniker T, Baumg€artner C, Eschricht S, Frey N, Katus HA, Chorianopoulos E. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin Res Cardiol 2011;100:879-885.
50. Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res 2016;61:44-50.
51. Intapad S, Ojeda NB, Varney E, Royals TP, Alexander BT. Sex-specific effect of endo-thelin in the blood pressure response to acute angiotensin II in growth-restricted rats. Hypertension 2015;66:1260-1266.
52. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1-77.
53. Vaneckova I, Dobesova Z, Kunes J, Vernerova Z, Zicha J. Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet. J Hypertens 2015;33:161-169.